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Thromboxane mediates renal hemodynamic response to infused angio-
tensin II. Since we had found that angiotensin II (Ang II), but not
phenylephrine (PE), increased the excretion of thromboxane (Tx) and
raised mean arterial pressure (MAP) by a Tx-dependent mechanism, we
tested the role of TxA2 in mediating Ang Il-induced changes in renal
hemodynamics. For series 1, groups of anesthetized rats received an
i.v. infusion of Ang 11(50 ng kg min'). When infused with a
vehicle, Ang II increased MAP, renal vascular resistance (RVR) and the
excretion of TxB2 factored by GFR. A PGH2-TxA2 receptor antagonist,
SQ-29,548, or three days of pretreatment With a TxA2 synthase inhibitor
UK-38,485, which reduced excretion of TxB2 by 80%, blunted the rise
in MAP and RVR induced by Ang II. In contrast, three days of
pretreatment with indomethacin did not alter the renal vascular re-
sponse to Ang II. For series 2, groups of rats received Ang II at a higher
rate (500 ng . kg min I) while the RPP was stabilized at + 11 to + 15
mm Hg with a suprarenal aortic clamp. SQ-29,548 and UK-38,485 both
prevented Ang 11-induced reductions in GFR and blocked 80% of the
increase in RVR. For series 3, infusions of phenylephrine at an
equipressor dose to series 2 of 30 g kg min with control of RPP
at +14 mm Hg also increased RVR but this was not blunted by
SQ-29,548. In conclusion: I.) infusion of Ang II increases excretion of
filtered TxB2, causes dose-dependent increases in RVR and, at high
doses, reduces GFR. 2.) Inhibition of TxA2 synthesis or blockade of
PGH2-TxA2 receptors prevents the fall in GFR and blunts 70 to 90% of
the increase in RVR. 3,) These effects are independent of RPP, appear
to be specific for Ang II, and are counteracted by release of vasodilator
cyclooxygenase products.
Angiotensin II (Ang II) is a powerful renal vasoconstrictor
which, when infused in high doses, can reduce the glomerular
filtration rate (GFR). There is evidence in a number of animal
models of Ang 11-related hypertension of increased thrombox-
ane A2 (TxA2) generation by the tissues and/or the kidneys and
a reduction in blood pressure (BP), or renal vascular resistance
(RVR), with drugs which blunt TxA2 generation or which block
prostaglandin (PG) H2-TxA2 receptors. These models include
the 2-kidney, 1-clip (2K,1C) renovascular rat [1—31, the sponta-
neously hypertensive rat (SHR) [4—6], the Dahl salt-sensitive rat
[7], the Lyon genetically hypertensive rat [8] and the rat model
of reduced renal mass [9—11]. Short- or long-term infusions of
Ang II into anesthetized or conscious rats increases the renal
excretion of TxB2 [12, 13]. Therefore, the present studies were
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designed to investigate the hypothesis that TxA2 mediates the
renal vascular actions of infused Ang II. We contrasted the
effect of Ang II infusion at two rates on renal hemodynamics in
groups of rats administered a vehicle (Veh), a TxA2 synthesis
inhibitor or a PGH2-TxA2 receptor antagonist. Since indometh-
acm has been shown to potentiate the effects of infused Ang II
on renal vasoconstriction in dogs [14—16] and salt-depleted rats
[17], we tested also the effects of indomethacin pretreatment on
the renal hemodynamic response to an Ang II infusion. During
infusion of Ang II at the higher rate, the renal perfusion
pressure (RPP) was controlled to the same level as at the lower
rate to allow a comparison of the dose-response relationships
without the confounding effects of large differences in the RPP.
Since we found that the infusion of the a-adrenoreceptor
agonist phenylephrine (PE) did not increase the excretion of
TxB2 and the pressor response to PE was unaffected by a
PGH2-TxA2 receptor antagonist [12], we also assessed the
effects of the PGH2-TxA2 receptor antagonist on the renal
vasoconstrictor response to PE. Preliminary accounts of some
of this work have been published [18, 19].
Methods
Animal preparation
Male Sprague-Dawley rats (175 to 250 g) were maintained on
standard rat chow (Rodent Laboratory Chow 5001, Ralston,
Purina, Co., St. Louis, Missouri, USA) and prepared for renal
clearance measurements [20]. Albumin (3 g dl"; Sigma
Chemical Co.) was dissolved in 0.154 M NaCl solution and
infused throughout at 0.5 ml 100 g body wt hr following
a priming dose of 0.5 ml to maintain a euvolemic state [21]. One
femoral artery was cannulated to measure the mean arterial
pressure (MAP) or the renal perfusion pressure (RPP). Both
jugular veins were cannulated; one transmitted an infusion of
[3H]-inulin (In; 0.1 Ci kg hr') and ['4C]-paraaminohip-
purate (PAH; 0.05 pCi . kg' . hr"'; both supplied by New
England Nuclear, Boston, Massachusetts, USA) which were
added to the maintenance infusion of albumin in saline. The
other was maintained patent with heparin saline and used to
infuse vehicle or drugs. The GFR was taken as the clearance of
In and the renal plasma flow (RPF) as the clearance of PAH;
renal extraction of PAH was not assessed.
Forty-five minutes elapsed following completion of surgery
before any measurements were made. Thereafter, there was a
basal urine collection period of 30 minutes; blood was sampled
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Table 1. Summary of the experimental groups
3
at the mid-point and replaced with an equal volume of albumin-
saline solution. This was followed by a 15-minute equilibration
period and a second experimental period of 30 minutes with
blood sampled at the mid-point, during which vehicle (Veh),
Ang II or PE were infused. Ten groups of rats were studied. The
numbers of animals in each group, and a summary of their
preparation are contained in Table 1.
UK-38,485 is an imidazole-derived inhibitor of TxA2 syn-
thase [221. At concentrations which produce considerable inhi-
bition of TxA2 synthase, it does not alter the activity of
cyclooxygenase, lipoxygenase or angiotensin converting en-
zyme [22]. We found previously that although it did not produce
reliable inhibition of TxB2 excretion or blockade of Ang II
pressor responses when given shortly before testing, when
given for three days before testing it produced uniform suppres-
sion of TxB2 and Ang II pressor responses. Moreover, this
dosing schedule did not alter basal or Ang Il-stimulated levels
of excretion of PGE2 or the prostacyclin metabolite 6kPGFI
[18]. Therefore, animals in the groups that required inhibition of
TxA2 synthase received three days of pre-treatment with UK-
38,485(100mg kg' day i.p.) while those in the remaining
group received vehicle injections.
SQ-29,548 is a structural analogue of the PG endoperoxide,
PGH2 and of TxA2 [23]. These two vasoconstrictor PG's share
a common receptor which is inhibited reversibly by this drug
[23]. SQ-29,548 does not inhibit cyclooxygenase or TxA2 syn-
thase in vitro [23]. However, this dose of SQ-29,548 totally
blocks the renal vasoconstriction and reduction in GFR induced
by an infusion of the TxA2 mimetic, U-46,619 [24]. In contrast
to the delayed effects of UK-38,485, we found that SQ-29,548
produced a powerful blockade of Ang Il-induced pressor re-
sponses [18] or U-46,619-induced renal vasoconstriction [24]
shortly after administration [18]. Therefore, SQ-29,548 was
given as a bolus dose on completion of surgery followed by a
maintenance infusion (8 mg kg' and 8 mg kg' hr). We
have shown previously that the MAP and the renal hemody-
namics remain stable during infusion of SQ-29,548 [24]. Indo-
methacin (Indo; Sigma Chemical Corp.) is a cyclooxygenase
inhibitor. When given as two oral doses of 5 mg by gavage 15
and one hour before anesthesia, we have shown that it reduces
the excretion of PGE2, 6kPGF1,, and TxB2 by 80 to 95% [21].
Thus, rats of this group received indomethacin using this dosing
schedule.
The results of the initial series indicated that UK-38,485 and
SQ-29,548 moderated Ang Il-induced pressor responses even at
the lower rate of Ang II infusion of 50 ng kg' min'.
Therefore, a second series was undertaken to test the effects of
these drugs during a higher rate of Ang II infusion (500
mg kg' min I) and with regulation of renal perfusion pres-
sure (RPP) at the same level as at the lower rate of Ang II
infusion. Rats of series 3 received an infusion of phenylephrine
at 30 ig kg' min which we had found previously to
increase MAP comparably to the higher dose of Ang II by 40 to
60 mm Hg [18]. To regulate RPP, a suprarenal aortic clamp was
adjusted during the infusion of Ang II or phenylephrine in series
2 and 3 to limit the rise in RPP to the level produced by the
lower rate of infusion of Ang II into vehicle-treated rats of
series 1.
Chemical methods and calculations
Na was measured in a flame photometer (Instrumentation
Laboratories, Lexington, Massachusetts, USA) and chloride
(Cl) in a chloride meter (Corning Medical, Medfield, Massachu-
setts, USA). [3H] and ['4C] were analyzed in a liquid scintilla-
tion counter (Beckman Instruments, Fullerton, California,
USA) with correction for quenching and cross-counting. Since
Ang II altered the GFR, data for Na and Cl excretion were
transformed into fractional excretions (FE) by dividing the
urine-to-plasma concentration ratios for these ions by the
urine-to-plasma concentration ratio for In. The RPF was esti-
mated in these studies from the clearance of PAH, assuming a
constant renal extraction of PAH (EPAH). Renal vasoconstric-
tor agents such as Ang II normally do not change EPAH
although, where RBF is greatly reduced, EPAH may rise,
leading to a small underestimation of the degree of renal
vasoconstriction [25]. We found previously that neither hyper-
chloremia, which stimulated endogenous TxA2 generation
within the kidney, nor indomethacin, which blocked TxA2
generation, altered EPAH in the anesthetized rat [26]. Therefore,
Group
Number
of rats
studied
Three-day
pre-tx 1
Gavage 15 &
hr before
Infusion
throughout
study
Control
of RPP
Period I
infusion
Period 2
infusion
Series 1
1 16 Veh None Veh No Veh Veh
2 8 Veh None Veh No Veh Ang II (LD)
3 9 UK None Veh No Veh Ang II (LD)
4 8 Veh None SQ No Veh Ang II (LD)
5 8 Veh Indo Veh No Veh Ang II (LD)
Series 2
8 Veh None Veh Yes Veh Ang II (HD)
9 Veh None SQ Yes Veh Ang II (HD)
8 UK None Veh Yes Veh Ang II (HD)
6
7
8
Series
9 8 None None Veh Yes Veh PE
10 8 None None SQ Yes Veh PE
Abbreviations are: RPP, renal perfusion pressure; Veh, vehicle; Ang II, angiotensin II; LD, lower dose (50 ng kg' . min); HD, higher dose(500 ng kg . min); SQ, SQ-29,548 (8 mg kg' and 8 mg .kg1 hr); UK, UK-38,485 (100mg. kg . day' i.p. x3); Indo, indomethacin
(5 mg kg x 2 p.o.); PE, phenylephrine (30 kg . min').
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Table 2. Data for series 1
RVR
Group
MAP
mm Hg
GFR
ml.min'•
100 g
RBF
mlmin.
100 g'
FF
%
mm Hg. UV
ml'min pJ.mi,r'.
100 g' 100 g'
FENa FEc PRA
ngm1'-hr'%
Group 1 (N 16)
I. Before 110 3 0.75 0.04 4.59 0.37 29.6 1.4 26.4 2.3 2.0 0.3 0.07 0.02 0.11 0.05 28.8 2,2
2. Vehicle 108 2 0.70 0.03 4.41 0.33 27.6 1.5 26.2 1.8 5.7 1.5 0.20 0.08 0.37 0.15 29.6 2.5
—2 1 —0.05 0.03 —0.18 0.17 —2.1 0.7 —0.2 1.5 +3.7 0.9 +0.13 0.04 +0.26 0.15 +0.8 1.3
Group 2 (N = 8)
1. Before 118 2 0.79 0.05 4.13 0.29 35.1 1.4 29.4 2.l 1.1 0.1 0.05 0.01 0.16 0.02 31.6 3.4
2. Ang II 130 4 0.63 0.07 3.13 0.42 38.8 2.0 46.7 6.1 10.2 3.4 0.74 0.27 2.20 0.91 6.0 1.0
z +12 2 —0.16 0.05 —1.00 0.26 +3.6 1.1 +17.3 5.2 +9.1 1.8 +0.69 0.26 +2.04 0.89 —24.6 3.2
Group 3 (N = 9)
1. UK Ill 3 0.87 0.07 5.06 0.38 30.8 0.7 23.2 2.3 1.2 0.2 0.07 0.01 0.17 0.03 35.3 3.7
2. UK + Ang II 118 3 0.79 0.06 4.66 0.52 32.0 1.4 28.1 3.5 7.4 2.4 0.77 0.26 1.98 0.53 10.4 2.1
+7 2 —0.08 0.05 —0.40 0.40 +1.2 1.0 +4.9 2.0 +6.2 1.5 +0.70 0.25 + I.81 0.49 —24.9 2.9
Group 4 (N = 8)
1. SQ 110 2 0.73 0.06 4.73 0.74 31.1 3.8 29.4 6.1 1.2 0.3 0.05 0.01 0.15 0.02 44.3 3.4
2. SQ + Ang II 115 3 0.76 0.06 4.50 0.68 33.6 4.1 32.9 1.2 3.9 7.7 0.35 0,17 0.79 0.15 9.2 0.8
L +5 2 +0.03 0.05 —0.24 0.18 +2,5 0.9 +3.5 2.2 +2.7 0.7 +0.31 0.17 +0.64 0.14 —31.0 7.0
Group 5 (N 6)
I. Indo 115 4 0.65 0.10 4.95 1.14 26.5 3.1 28.9 5.1 0.7 0.1 0.01 0.00 0.01 0.00
2. Indo + Ang II 122 4 0.54 0.11 3.04 0.42 31.3 1.4 43.1 5.2 1.1 0.7 0.21 0.16 0.37 0.21
+7 3 —0.11 0,05 —1.90 0.85 +4.8 2.0 +14.2 3.6 +0.5 0.3 +0.21 0.15 +0.36 0.21
P value by
ANOVA
Effects of Ang II: <0.00001 NS NS <0.0001 <0.0001 <0.05 <0.005 <0.005 <0.0001
Effects of drugs
on response to
Ang II:
• UK <0.05 NS NS NS <0.005 NS NS NS NS
• SQ <0.02 NS NS NS <0.002 <0.05 NS <0.05 NS
• Indo NS NS NS NS NS <0.01 NS <0.01 —
Mean arterial pressure, renal hemodynamics, excretion of fluid and ions and plasma renin activity before and during Ang II infusion at 50
ng. kg' - min and effects of a TxA2 synthesis inhibitor and a PGH2-TxA2 receptor antagonist. Data are presented as mean SEM (N = number
of rats studied). Abbreviations are: Ang 11, angiotensin 11 infusion; SQ, SQ-29,548 (8 mg . kg' and 8 mg . kg' . hr); UK, UK-38,485 (100
mg kg' day x3); Indo, indomethacin (5 mg kg' >< 2 p.o.).
since renal vein blood sampling itself perturbs renal hemody-
namics, EPAH was not measured in these experiments. Renal
blood flow (RBF) was calculated from RPF and hematocrit and
RVR from MAP factored by RBF.
Urine for TxB2 analysis in series 1 was stored at —70°C. The
details of the methods used to extract, purify and assay the
samples, and to measure the individual sample recoveries, as
well as the performance characteristics and validation of the
assay have been published 2l]. Since the infusion of Ang II
altered GFR, data for TxB2 excretion were factored by GFR.
Blood for plasma renin activity (PRA) was drawn into EDTA-
containing tubes and the plasma separated and stored at —70°C.
For assay, samples were thawed to 4°C and the rate of anglo-
tensin I generated over a 90 minute incubation at 37°C assessed
with a radioimmunoassay (Travenol, Genentech Diagnostics,
Cambridge, Massachusetts, USA) [20J.
Drugs used
Angiotensin II (Sigma Chemical Co.) and phenylephrine
(Sigma) were dissolved in 0,15 M NaCl. SQ-29,548 (Squibb
Institute for Medical Research, Summit, New Jersey, USA)
was dissolved in ethanol with equimolar TRIS chloride salt,
dried under nitrogen gas and diluted in 0.15 M NaCI. UK-38,485
(Pfizer Central Research, Groton, Connecticut, USA) was
dissolved in I N NaOH at pH 12.5, titrated with 1 N HCI to pH
8.5 and diluted with 0.15 M NaCl.
Statistical methods
The three series of experiments were analyzed separately. A
two-way analysis of variance (ANOVA) was used to assess the
separate effects of drugs (Ang II, PE or Veh) and treatments
(UK-38,485, SQ-29,548 or Veh). Where a statistically signifi-
cant effect was found, a post-hoc unpaired t-test was applied to
detect the group(s) which differed. Data are presented as mean
SEM and statistical significance taken at P < 0.05.
Results
Table 2 shows data for animals of series I which received an
infusion of Ang II at 50 ng ' kg' min'. In the basal state,
animals which had received UK-38,485 for three days before
study had rather higher values for GFR and RBF and lower
values for RVR compared to the other groups which had
received no pretreatment. Indomethacin pretreatment led to
lower basal rates of FENa and FE1. Otherwise, the parameters
of renal function were similar between groups in the basal state.
The vehicle infusion did not alter the MAP, GFR, RBF, RVR or
FE1. However, there was a small, but consistent, reduction in
the FF and increase in the UV and FENa. The Ang II infusion
at SOng kg ' min' caused a pressor response of +12 2
mm Hg. When analyzed by ANOVA, this dose of Ang II did not
significantly alter the GFR or RBF, but lead to a modest
increase in the FF and a more striking increase in RVR of 60%.
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Table 3. Data from series I
Group
Excretion
of TxB2
pg min'
Excretion of
TxB2/GFRpg m1'
Group I control (N = 16)
1. Before 45 6 22.6 3.3
2. Vehicle 58 10 29.8 9.6
A +12±7 +7.0±4.8
Group 2 (N = 8)
1. Before 62 7 30.6 3.9
2. Ang II 76 12 48.1 8.1
A +14 15 + 17.9 9.9
Group 3 (N = 9)
1. UK 7 2.9 02b
2. UK + Angil 33 9a 15.8 45b
A +27 9 +12.9 4.5
P value by ANOVA
Effects of Ang H:
Effects of UK on response to Ang II:
NS
NS
<0.05
NS
Data are presented as means SEM (N = number of rats studied).
a p < 0.05, ' P < 0.005 compared to group 2
There was an accompanying diuresis and increase in the frac-
tional excretions of Na and Cl. UK-38,485 pretreatment blunted
the Ang Il-induced pressor response by 41% and the increase in
RVR by 72%, while SQ-29,548 blunted the pressor response by
58% and the increase in RVR by 80%. Indomethacin did not
alter the renal hemodynamic responses to Ang II. Both SQ-
29,548 and indomethacin significantly blunted the Ang II-
induced diuresis and increase in FE1. In contrast, UK-38,485
did not modify Ang Il-induced diuresis or increases in fractional
excretion of Na or Cl. The PRA was profoundly suppressed
during infusion of Ang II in all groups studied.
Compared to the vehicle-infused control animals, the infusion
of Ang II at 50 ng . kg . min' did not significantly increase
the absolute rate of excretion of TxB2 but it did increase the
excretion of TxB2 factored by GFR (Table 3). Pre-treatment
with the TxA2 synthase inhibitor, UK-38,485 reduced the basal
rate of TxB2 excretion by greater than 90% and, although
infusion of Ang II still increased TxB2 excretion, it remained
suppressed in this group compared to animals receiving Ang II
during a vehicle infusion.
Table 4 shows data for the RPP and the renal function of
animals of series 2 which received an infusion of Ang H at 500
ng kg min' during control of RPP. The rise in RPP was
limited to a mean value of 15 mm Hg in the animals that
received Ang 11 alone. At this higher rate of infusion, Ang II
caused significant reductions in GFR and RBF, a striking rise in
FF and a tripling of RVR. Compared to the controls in group 1,
animals that had received UK-38,485 pretreatment or an infu-
sion of SQ-29,548, had no significant differences in the baseline
parameters. At this higher rate of Ang II infusion, both pre-
treatment with UK-38,485 and infusion with SQ-29,548 pre-
vented the Ang 11-induced fall in GFR, and blunted the rises in
FF and RVR. In contrast to the results in animals which had
received the lower rate of infusion, Ang II did not increase UV
or FENa; however, both UK-38,485 and SQ-29,548 caused
marked increases in diuresis and fractional excretion of Na
during Ang II infusion.
To determine whether the blunting of the RVR response by
the PGH2-TxA2 receptor antagonist was specific for Ang II, the
effects of SQ-29,548 on the renal vascular response to PE was
studied during control of RPP at the level of animals in series 2.
Table 5 shows that, compared to controls, the basal levels of
RPP and RVR were not altered in those that had received an
infusion of SQ-29,548. The rise in RPP with PE was regulated in
each group to 14 to 15 mm Hg by adjustment of the suprarenal
aortic clamp. The increase in RVR of 78% in animals receiving
the PE infusion alone was not significantly different from the
increase of 65% in those that were also receiving an infusion of
SQ-29,548.
Figure 1 shows the percentage changes in RVR and GFR
from basal values during infusion of Ang II at the two different
rates, and the effects of UK-38,485 or SQ-29,548. Ang II led to
a steep dose-dependent increase in RVR and a fall in GFR at the
higher dose. There was a profound, and very comparable,
degree of inhibition of renal vasoconstriction at both doses of
Ang II by UK-38,485 and SQ-29,548. Moreover, the fall in GFR
at the higher dose of Ang II infusion was effectively prevented
by both drugs.
Discussion
These studies have provided further evidence for an impor-
tant interaction between the renal TxA2 and Ang II systems.
The first indication that TxA2 might mediate some of the renal
actions of Ang II derived from studies by Stahl and colleagues
[1], who demonstrated increased renal TxB2 excretion and
increased TxB2 release from isolated glomeruli of kidneys taken
from rats with the 2K,IC model of renovascular hypertension.
These authors showed further that, in this model, reduction of
PG and TxA2 synthesis with indomethacin reduced the BP. This
finding was surprising since indomethacin administration to
dogs has been shown to potentiate the renal vasoconstriction
produced by infusion of Ang 11114—161. Subsequently, further
evidence that vasoconstrictor metabolites of cyclooxygenase,
such as TxA2, are of particular importance in the 2K,IC model
was provided by Himmelstein and Klotman [21 who showed
that a drug which inhibited PGH2-TxA2 receptors (GR-32,l91)
or one which inhibited TxA2 synthesis (UK-38,485) both in-
creased the GFR in the contralateral kidney and lowered the
BP. Our own results using the 2K,1C model show that indo-
methacin produces dose-dependent reductions in BP and that
infusion of SQ-29,548 reduces BP to normal levels [3]. An
interaction between TxA2 and Ang II had been demonstrated
also in the hydronephrotic, ureter-obstructed kidney. In this
model, there is increased renin secretion, increased TxB2
excretion and renal vasoconstriction. Inhibition of angiotensin
coverting enzyme (ACE) or TxA2 synthase increases RBF and
GFR suggesting that both Ang II and TxA2 contribute to renal
vasoconstriction [27, 28]. Although a part of the increased renal
TxA2 generation was ascribed to resident inflammatory cells, a
second component was dependent on increased Ang II produc-
tion [271. Thus, as in the present study, TxA2 may be mediating
some of the renal vasoconstrictor actions of Ang II in this
model. The details of the interaction between Ang H and TxA2
in other models of hypertension have not yet been so com-
pletely elucidated. However, the findings of our previous study
[18], and those of the present series, raises the possibility that
Ang Il-induced TxA2 generation could mediate some of the
systemic and renal vasoconstriction assigned to Ang II in these
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Table 4. Data for series I
models. This is of interest because TxA2 is not only a vasocon-
strictor and platelet aggregating agent, but also promotes
growth in vascular smooth muscle or mesangial cells [6, 291 and
might therefore provide an important link between Ang I!,
intraglomerular coagulation and structural changes in the blood
vessels and kidneys in hypertension. Indeed, in the rat model of
reduced renal mass, not only Ang II converting enzyme inhib-
itors, but also TxA2 synthase inhibitors can produce striking
amelioration of glomerular sclerosis, improvement of renal
function and reduction in proteinuria, hypertension and cardiac
hypertrophy [9—i 1].
Evidence for an interaction between TxA2 and Ang II has
derived both from experiments involving in vitro studies of
isolated glomeruli and in vivo infusion of Ang II. In studies of
isolated glomeruli, Ang II can activate phospholipases, release
arachidonate and cause dose-dependent stimulation of TxB2
release [4, 30—321. In contrast, the effects of norepinephrine on
glomerular TxB2 release are limited to potentiating the role of
other agonists [301. The renal excretion of both the prostacyclin
derivative, 6kPGF1 and TxB2 are increased during short-term
infusions of Ang II into anesthetized rats [18] and during
prolonged infusions of Ang II into conscious rats 113, 331. In a
previous study, infusion of Ang II at the dose equivalent to the
high dose used in these protocols was shown to increase the
excretion of TxB2 [18], whereas in the present study, infusion of
Ang II at the lower dose led to a more modest increase in TxB2
excretion which was apparent only when factored by GFR. This
suggests that there may be dose-dependent effects of Ang II on
renal TxA2 generation. The present finding that a TxA2 synthe-
sis inhibitor prevented renal vasoconstriction with infused Ang
II confirms a previous finding in which furegrelate was used to
inhibit TxA2 generation [34].
Prolonged infusion of Ang II into conscious rats receiving
saline to drink causes severe renal and vascular damage char-
acteristic of malignant hypertension and nephrosclerosis. In
this model, there is increased production of 6kPGF1, PGE2
and TxB2 by renal and vascular tissues [33, 35, 36). Although
the severe hypertension of this model is ameliorated by a
PGH2-TxA2 receptor antagonist, a TxA2 synthase inhibitor is
without effect [35, 36]. However, neither drug altered GFR and
the effect of the PGH2-TxA2 antagonist was limited to main-
taining RBF during a fall in BP [36]. Presumably, in this much
more severe model, there are fixed vascular and glomerular
lesions which prevent the major reversal of renal vasoconstric-
tion and the elevation of GFR that were found in the present
study after TxA2 synthesis inhibition or PGH2-TxA2 receptor
blockade. Since Mistry et al [35, 361 found that a PGH2-TxA2
receptor antagonist, but not a TxA2 synthesis inhibitor, lowered
BP and RVR in their model, they concluded that pressor
prostanoids such as PGH2 were of particular importance in
causing the hypertension and renal vasoconstriction. In con-
trast, we observed that a TxA2 synthase inhibitor produced a
substantial blockade of Ang Il-induced pressor responses [18]
or renal hemodynamic changes which were strictly comparable
to those produced by a PGH2-TxA2 receptor antagonist. It is
possible that a component of the response to the TxA2 synthesis
inhibitor might be mediated by increased PG!2 synthesis since
PG!2 infusion in the rat can reduce RVR [37]. However, we
have found that a similar three-day pretreatment regimen with
UK-38,485 does not increase the release of the PG!2 metabolite,
6kPGF1 or PGE2 from isolated rat aortic strips studied ex vivo
(unpublished observation), nor does it increase the basal or the
Ang II- or PE-stimulated rates of excretion of these PG's [18].
At the same level of RPP, SQ-29,548 and UK-38,485 produced
RVR
GFR RBF mm Hg. UV
RPP mlmin' ml.min' FF m1' min'- .d min'• FENa
Group mm Hg 100 g' 100 g' % 100 g' 100 g' %
110
108
—2
2
2
1
0.75 0.04
0.70 0,03
—0.05 0.02
4.6 0.4
4.4 0.3
—0.2 0.2
30.0
27.5
—2.1
1.4
1.5
0.7
26.4 2.3
26.2 1.8
—0.2 1.5
2.0 0.3
4.4 1.4
+2.4 0.9
0.09 0.03
0.25 0.14
+0.16 0.10
123
138
+15
5
5
2
0.69 0.08
0.43 0.04
—0.26 0.10
4.2 0.5
1.6 0.2
—2.5 0.6
32.1
50.1
19.8
1.7
1.6
2.2
31.5 2.8
92.4 10.6
+60.9 22.4
1.5 0.3
2.1 0.5
+0.6 0.7
0.06 0.01
0.24 0.06
+0.18 0.05
117
128
+11
5
4
2
0.96 0.08
0.96 0.06
0.00 0.06
5.4 0.8
3.9 0.3
—1.5 0.6
30.4
40.1
+9.8
2.5
3.3
2.2
29.4 8.0
34.9 4.2
+5.5 4.5
1.6 0.2
13.2 1.8
+11.6 1.7
0.09 0.02
1.46 0.27
+1.37 0.25
114
127
+13
2
5
1
0.87 0.09
0.80 0.05
—0.07 0.06
4.4 0.6
3.0 0.4
—1.4 0.5
27.4
38.9
+11.4
1.4
3.2
2.8
21.5 3.5
34.1 4.7
+12.6 3.6
1.6 0.1
6.6 1.2
+5.0 1.2
0.03 0.01
0.79 0.29
+0.76 0.29
<0.0001
Group I (N = 16)
1. Before
2. Vehicle
Group 5 (N = 8)
1. Before
2. Ang II
Group 6 (N = 8)
1. UK
2. UK + Ang II
Group 7 (N 9)
1. SQ
2. SQ + Ang II
'
P value by ANOVA
Effects of Ang II: < 0.02 < 0.0002 < 0.00001 < 0.00001 NS NS
Effects of drugs on
response to Ang II:
• UK NS <0.01 NS <0.005 <0.0001 <0.001 <0.005
• SQ NS <0.05 NS <0.02 <0.0001 <0.02 <0.0002
Renal perfusion pressure, renal hemodynamics and excretion of fluid and ions before and during vehicle or Ang 11 infusion at 500
ng. kg' min and effects of a TxA2 synthetase inhibitor and PGH2-TxA2 receptor antagonist. Data are presented as mean SEM (N number
of rats studied). Abbreviations are: Ang I!, angiotensin H infusion; SQ, SQ-29,548 (8 rug kg' and 8 mg . kg . hC'); UK, UK-38,485 (100
mg kg' day x3).
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Table 5. Data from series 3
RVR
RPP mmHg.mt'-
Group mm Hg min 100g'
Group 8 (N = 8)
1. Before 90 0 26.8 3.5
2. PE 104 0 47.8 9.2
3. +14 1 +21.0 7.3
Group 9 (N = 8)
1, SQ 90±3 27.2±2.7
2. SQ + PE 105 3 45.0 5.5
3. +15 I + 17.8 5.0
Effects of PE:
Effects of SQ on res
P <0.0001
ponse to PE: NS
P <0.001
NS
Renal perfusion pressure and renal vascular resistance shown during
vehicle or phenylephrine infusion at 30 g . kg mln' and effects of
a PGH2-TxA2 receptor antagonist. Data are presented as mean SEM(N = number of rats studied). Abbreviations are: PE, phenylephrine
infusion; SQ, SQ-29,548 (8 trig kg and 8 mg kg hr).
a remarkably comparable and uniform blockade of Ang II-
induced increases in RVR and decreases in GFR, both at the
low and high pressor doses (Fig. 1). Therefore, the results of the
present experiments implicate TxA2, rather than PGH2, as the
predominant pressor prostanoid in the Ang Il-induced increase
in RVR and reduction in GFR in these anesthetized rats infused
short-term with pressor doses of Ang II. The very large fraction
of the Ang Il-induced increase in renal vasoconstriction which
these pharmacologic studies have assigned to TxA2 is consis-
tent with the findings that TxA2 is a very potent and selective
renal vasoconstrictor agent [38, 39].
There were some differences between the effects of the drugs
on the Ang II responses at the two doses. At the lower dose,
Ang II increased the FF modestly; this response was not
blocked by either the TxA2 synthesis inhibitor or the PGH2-
TxA2 receptor antagonist or the cyclooxygenase inhibitor. At
the high dose, Ang II produced a much more striking rise in FF
despite a fall in GFR, and these actions were blunted by both
UK-38,485 and SQ-29,548. The lower FF during Ang II infusion
in rats receiving the blocking drugs might diminish the fraction
of fluid reabsorbed in the proximal tubule [40] which could
contribute to the diuresis and natriuresis that these drugs
produced at the higher rate of infusion of Ang II. At the lower
dose of Ang II, where there were no consistent effects of the
drugs on the GFR or the FF, SQ-29,548 and indomethacin
actually blunted the diuresis and chloriuresis. Whether this
reflects a specific interference with the complex, biphasic
effects of Ang II on proximal reabsorption [40, 41] cannot be
answered with clearance methods. However, the effects of
SQ-29,548 and indomethacin in blunting Ang 11-induced diure-
sis and chloriuresis were not seen in UK-38,485-pretreated rats,
which suggests that they might be due to blockade of PGH2
synthesis or receptors. At the higher rates of Ang II infusion
where RPP was controlled, both SQ-29,548 and UK-38,485
promoted a diuresis and natriuresis during Ang II infusion
which is consistent with our preliminary findings which have
implicated TxA2 in enhancing Cl reabsorption in the loop of
Henle [42].
Both TxA2 synthesis inhibition and PGH2-TxA2 receptor
blockade fully prevented the fall in GFR during high rates of
Ang II infusion when RPP was controlled. Therefore, it is
Fig. 1. Mean SEM values for percentage changes in renal vascular
resistance and glomerular filtration rate from baseline values as a
function of the rate of infusion of angiotensin II in rats which had
received no other drug treatments (vehicle, 0), pretreatment with a
TxA2 synthesis inhibitor (UK-38,485, L) or a PGH2-TxA2 receptor
antagonist (SQ-29,548, A). Compared to infusion of Ang II with
vehicle: *, P <0.05; **, P < 0.01.
possible that these drugs may have some special value in certain
Ang Il-dependent states, such as the post-stenotic kidney in
renovascular hypertension, where non-selective inhibition of
angiotensin converting enzyme can lead to a sharp fall in GFR
[43].
In the present series, the absence of a consistent change in
the renal vasoconstrictor response to Ang II after indomethacin
administration, when contrasted with the blunting of renal
vasoconstriction with drugs which inhibit TxA2 synthesis or
receptors, may imply that Ang II induces a balanced release of
vasodilator and vasoconstrictor cyclooxygenase products in
this euvolemic model. Previous studies have shown that indo-
methacin can accentuate pressor and renal vasoconstrictor
responses to Ang II which are pronounced in the dog [14—16].
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However, interpretation of these findings is complicated be-
cause aspirin is without effect [16] and indomethacin can
potentiate mesenteric vascular resistance by an action indepen-
dent of cyclooxygenase inhibition [44]. Moreover, in the rat or
human, indomethacin can augment Ang Il-induced systemic
and renal vasoconstrictin after dietary salt restriction but not
after salt loading [45, 17] or administration or mineralocortico-
steroids [461. Indeed, in the rat PGI2 does not constrict the
juxtamedullary afferent arteriole when applied directly, and
PGE2 is a vasoconstrictor which potentiales the actions of Ang
II in this preparation [47]. Indomethacin does not alter consis-
tently the response of Ang II added to the bathing solution of
isolated cortical afferent arterioles of the rat [48]. Moreover, in
the context of a sustained increase in renin secretion and
plasma Ang II levels in the 2K, 1C rat model of renovascular
hypertension, indomethacin causes dose-dependent reductions
in blood pressure [1, 3]. Therefore, the absence of a consistent
change in renal vascular responsiveness to Ang II after indo-
methacin administration in the present series of euvolemic rats
may be explained by some other action of indomethacin that is
distinct from effects on PG synthesis.
Phenylephrine was selected as a contrast agent for Ang II
since we found previously that, at equipressor rates of infusion,
it did not increase TxB2 excretion nor was the rise in HP
attenuated by SQ-29,548 [18]. Moreover, using the perfused
mesentery preparation in the rat, Jackson [49] found that a
TxA2 synthesis inhibitor did not blunt the vasoconstrictor
response to addition of norepinephrine to the perfusate. The
present study shows that, in contrast to Ang II, the PE-induced
rise in RVR was not moderated by SQ-29,548. This indicates
that TxA2 may have a specific role in mediating the pressor and
renal vasoconstrictor actions of Ang II.
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